Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Humacyte, Inc. Warrant (HUMAW)

Biological Products, (no Disgnostic Substances)

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/27/2021

Market Cap

725,524,386

Shares Outstanding

103,460,000

Weighted SO

N/A

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

HUMA --.--%

EFTRW --.--%

QSIAW --.--%

CELUW --.--%

ROIVW --.--%

Beta

1.5190

Last Div

0.0000

Range

2.0-2.17

Chg

-0.1000

Avg Vol

N/A

Mkt Cap

725524386

Exch

NASDAQ

Country

US

Phone

N/A

DCF Diff

6.1926

DCF

0.2174

Div Yield

0.0000

P/S

71.0133

EV Multiple

-7.1424

P/FV

-27.0478

Div Yield %

0.0000

P/E

-5.4783

PEG

0.0201

Payout

0.0000

Current Ratio

5.4125

Quick Ratio

5.4125

Cash Ratio

5.2691

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

263.8528

CCC

-263.8528

Gross Margin

0.2301

Op Margin

-9.9056

Pretax Margin

-12.9435

Net Margin

-12.9435

Eff Tax Rate

0.1778

ROA

-1.0100

ROE

-11.5412

ROCE

-0.8868

NI/EBT

1.0000

EBT/EBIT

1.3067

EBIT/Rev

-9.9056

Debt Ratio

0.1296

D/E

-0.6337

LT Debt/Cap

-1.1488

Total Debt/Cap

-1.7299

Int Coverage

-42.9069

CF/Debt

-4.5020

Equity Multi

-4.8885

Rec Turnover

0.0000

Pay Turnover

1.3833

Inv Turnover

0.0000

FA Turnover

0.2609

Asset Turnover

0.0780

OCF/Share

-0.6771

FCF/Share

-0.6874

Cash/Share

0.7851

OCF/Sales

-7.4791

FCF/OCF

1.0151

CF Coverage

-4.5020

ST Coverage

-28.8005

CapEx Coverage

-66.2553

Div&CapEx Cov

-66.2553

P/BV

-27.0478

P/B

-27.0478

P/S

71.0133

P/E

-5.4783

P/FCF

-9.3538

P/OCF

-9.4809

P/CF

-9.4809

PEG

0.0201

P/S

71.0133

EV Multiple

-7.1424

P/FV

-27.0478

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 11, 21:14 HUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Jan 05, 18:23 ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA Benzinga Jan 02, 21:06 Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit GlobeNewswire Inc. Dec 30, 23:54 ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Dec 24, 20:58 HUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About the Class Action Against Humacyte, Inc. GlobeNewswire Inc. Dec 24, 03:55 ROSEN, A LONGSTANDING FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Dec 21, 03:58 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Dec 20, 03:47 Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma GlobeNewswire Inc. Dec 20, 02:00 HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm GlobeNewswire Inc. Dec 20, 00:23 DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte GlobeNewswire Inc. Dec 10, 23:49 DEADLINE ALERT for PACS, HAS, ASML, HUMA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire Inc. Nov 30, 18:49 ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Nov 30, 18:49 ????????? ROSEN ?? Humacyte, Inc. ????? HUMA ????????????????????? GlobeNewswire Inc. Nov 28, 00:15 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA GlobeNewswire Inc. Nov 26, 22:44 SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte GlobeNewswire Inc. Nov 26, 02:00 HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm GlobeNewswire Inc. Nov 24, 05:23 Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action Benzinga Oct 23, 01:03 INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors

Revenue Product Segmentation